Free Trial

Innoviva (INVA) Stock Forecast & Price Target

$16.22
+0.06 (+0.37%)
(As of 06/18/2024 ET)

Innoviva - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Consensus Price Target

N/A

TypeCurrent Forecast
6/20/23 to 6/19/24
1 Month Ago
5/21/23 to 5/20/24
3 Months Ago
3/22/23 to 3/21/24
1 Year Ago
6/20/22 to 6/20/23
Consensus Rating
Buy
N/A
Buy
Hold
Strong Buy
0 Strong Buy rating(s)
N/A
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
N/A
1 Buy rating(s)
1 Buy rating(s)
Hold
0 Hold rating(s)
N/A
0 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
N/A
0 Sell rating(s)
1 Sell rating(s)
Consensus Price TargetN/AN/A$22.50$15.17
Forecasted UpsideN/AN/A89.87% Upside33.86% Upside
Get Innoviva Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for INVA and its competitors with MarketBeat's FREE daily newsletter.

INVA Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

INVA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Innoviva Stock vs. The Competition

TypeInnovivaMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.70
2.50
Consensus RatingBuyModerate BuyHold
Predicted Upside1,068.17% Upside11.30% Upside
News Sentiment RatingPositive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
6/18/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight
4/20/2023EF Hutton Acquisition Co. I
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy$22.50+89.87%
3/3/2023The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral$15.00 ➝ $13.00+16.70%
3/3/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetUnderweight$13.00 ➝ $10.00-9.09%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 06:07 AM ET.

INVA Forecast - Frequently Asked Questions

What is Innoviva's purchase recommendation?

According to the research reports of 1 Wall Street equities research analysts, The consensus rating for Innoviva stock is Buy based on the current 1 buy rating for INVA. Learn more on INVA's analyst rating history.

Do Wall Street analysts like Innoviva more than its competitors?

Analysts like Innoviva more than other "medical" companies. The consensus rating for Innoviva is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how INVA compares to other companies.

What analysts cover Innoviva?

Innoviva has been rated by research analysts at Cantor Fitzgerald in the past 90 days.


Stock Forecasts and Research Tools

This page (NASDAQ:INVA) was last updated on 6/19/2024 by MarketBeat.com Staff

From Our Partners